Sanofi SA - רווח למניה ב-12 החודשים האחרונים SNY

This chart of relative EPS YoY TTM changes demonstrates the impact of the success of Sanofi (SNY) flagship immunology drug on margins. Profit growth is based on the low cost of mass-producing medications and a focus on biotechnology for rare pathologies. The -30.30 mark reflects the latest data, confirming that operating leverage effectively offsets the costs of updating the R&D portfolio.
SNY (sanofi.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Patent protection for Sanofi (SNY) drugs creates high barriers to entry, which directly impacts the efficiency of profit generation. By analyzing the YoY TTM growth of net income per share, an investor assesses the 12-month EPS growth trend to determine the fair value of the business. This chart reflects the company's ability to monetize innovation despite regulatory pressure in Europe. The positive momentum confirms the resilience of the operating model and justifies the market premium for control.